SOUTH SAN FRANCISCO, Calif.,
Oct. 30, 2018 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its third quarter 2018 financial
results after market close on Tuesday,
November 6, 2018. Rigel senior management will follow
the announcement with a live conference call and webcast at
5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial
results and give a company update.
Participants can access the live conference call by dialing
(855) 892-1489 (domestic) or (720) 634-2939 (international) and
using the Conference ID number 1398326. The conference call
will also be webcast live and can be accessed from Rigel's website
at www.rigel.com. The webcast will be archived and
available for replay for 30 days after the call via the Rigel
website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is TAVALISSE™
(fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase
(SYK) inhibitor, for the treatment of adult patients with chronic
immune thrombocytopenia who have had an insufficient response to a
previous treatment. Rigel's clinical programs include an upcoming
Phase 3 study of fostamatinib in autoimmune hemolytic anemia and an
ongoing Phase 1 study of R835, a proprietary molecule from its
interleukin receptor associated kinase (IRAK) program. In addition,
Rigel has product candidates in development with partners BerGenBio
AS, Daiichi Sankyo, and Aclaris Therapeutics.
Please see www.TAVALISSE.com for the full Prescribing
Information.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
Media Contact: Jessica Daitch
Phone: 917.816.6712
Email: jessica.daitch@syneoshealth.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2018-financial-results-300739886.html
SOURCE Rigel Pharmaceuticals, Inc.